Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib

We report the case of an 85‐year‐old man who was surgically diagnosed with lung adenocarcinoma (pT2aN1M0 stage IIA). He was administered platinum combination chemotherapy as first‐line treatment for lung cancer recurrence. The patient's pleural fluid sample was obtained and analysed using a nex...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakura, Seigo, Kobayashi, Nobuaki, Somekawa, Kohei, Masumoto, Nami, Kudo, Makoto, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611516/
https://www.ncbi.nlm.nih.gov/pubmed/31312453
http://dx.doi.org/10.1002/rcr2.453
_version_ 1783432710500384768
author Katakura, Seigo
Kobayashi, Nobuaki
Somekawa, Kohei
Masumoto, Nami
Kudo, Makoto
Kaneko, Takeshi
author_facet Katakura, Seigo
Kobayashi, Nobuaki
Somekawa, Kohei
Masumoto, Nami
Kudo, Makoto
Kaneko, Takeshi
author_sort Katakura, Seigo
collection PubMed
description We report the case of an 85‐year‐old man who was surgically diagnosed with lung adenocarcinoma (pT2aN1M0 stage IIA). He was administered platinum combination chemotherapy as first‐line treatment for lung cancer recurrence. The patient's pleural fluid sample was obtained and analysed using a next‐generation sequencer, which demonstrated the presence of mesenchymal–epithelial transition gene (MET) exon 14 skipping mutations. As the patient developed progressive disease after receiving first‐line chemotherapy, crizotinib was administered as the second‐line treatment. The treatment was effective, and the patient had a stable disease for 7 months. This case suggests that crizotinib is effective against non‐small cell lung cancer with MET exon 14 alterations.
format Online
Article
Text
id pubmed-6611516
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-66115162019-07-16 Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib Katakura, Seigo Kobayashi, Nobuaki Somekawa, Kohei Masumoto, Nami Kudo, Makoto Kaneko, Takeshi Respirol Case Rep Case Reports We report the case of an 85‐year‐old man who was surgically diagnosed with lung adenocarcinoma (pT2aN1M0 stage IIA). He was administered platinum combination chemotherapy as first‐line treatment for lung cancer recurrence. The patient's pleural fluid sample was obtained and analysed using a next‐generation sequencer, which demonstrated the presence of mesenchymal–epithelial transition gene (MET) exon 14 skipping mutations. As the patient developed progressive disease after receiving first‐line chemotherapy, crizotinib was administered as the second‐line treatment. The treatment was effective, and the patient had a stable disease for 7 months. This case suggests that crizotinib is effective against non‐small cell lung cancer with MET exon 14 alterations. John Wiley & Sons, Ltd 2019-07-05 /pmc/articles/PMC6611516/ /pubmed/31312453 http://dx.doi.org/10.1002/rcr2.453 Text en © 2019 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Katakura, Seigo
Kobayashi, Nobuaki
Somekawa, Kohei
Masumoto, Nami
Kudo, Makoto
Kaneko, Takeshi
Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
title Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
title_full Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
title_fullStr Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
title_full_unstemmed Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
title_short Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
title_sort non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611516/
https://www.ncbi.nlm.nih.gov/pubmed/31312453
http://dx.doi.org/10.1002/rcr2.453
work_keys_str_mv AT katakuraseigo nonsmallcelllungcancerwithmesenchymalepithelialtransitiongeneexon14skippingmutationtreatedwithcrizotinib
AT kobayashinobuaki nonsmallcelllungcancerwithmesenchymalepithelialtransitiongeneexon14skippingmutationtreatedwithcrizotinib
AT somekawakohei nonsmallcelllungcancerwithmesenchymalepithelialtransitiongeneexon14skippingmutationtreatedwithcrizotinib
AT masumotonami nonsmallcelllungcancerwithmesenchymalepithelialtransitiongeneexon14skippingmutationtreatedwithcrizotinib
AT kudomakoto nonsmallcelllungcancerwithmesenchymalepithelialtransitiongeneexon14skippingmutationtreatedwithcrizotinib
AT kanekotakeshi nonsmallcelllungcancerwithmesenchymalepithelialtransitiongeneexon14skippingmutationtreatedwithcrizotinib

Ejemplares similares